Core Insights - Tarsus Pharmaceuticals reported a significant increase in net product sales of XDEMVY, reaching $78.3 million, which represents a 217% year-over-year growth and an 18% increase over Q4 2024 [4][10] - The company has strengthened its financial position by raising approximately $135 million through a public equity offering, resulting in cash, cash equivalents, and marketable securities totaling approximately $408 million as of March 31, 2025 [4][10] - Tarsus is on track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the treatment of Ocular Rosacea in the second half of 2025 [4][10] Financial Performance - The first quarter of 2025 saw net product sales of XDEMVY at $78.3 million compared to $24.7 million in the same period of 2024, driven by approximately 72,000 bottles delivered to patients, up from 26,000 bottles year-over-year [10][19] - Cost of sales increased to $5.2 million from $1.7 million in the prior year, attributed to manufacturing costs and royalties [10][19] - Research and development expenses rose to $14.4 million from $12.1 million, while selling, general, and administrative expenses increased to $85.0 million from $51.6 million, primarily due to higher payroll and marketing costs [10][19] - The net loss for the quarter was $25.1 million, an improvement from a net loss of $35.7 million in the same quarter of 2024, with a basic and diluted net loss per share of $(0.64) compared to $(1.01) [10][19] Business Highlights - XDEMVY is positioned to be one of the fastest-growing anterior segment medicines, with broad commercial reimbursement coverage extending to over 90% of covered lives [4][10] - The company reported a gross-to-net discount of approximately 47% and a 23% increase in the number of bottles dispensed compared to Q4 2024 [4][10] - Direct-to-consumer advertising led to a 140% increase in average weekly website visits in March 2025 compared to December 2024 [4][10] - Tarsus is advancing its pipeline with multiple catalysts expected in 2025, including a meeting with regulatory authorities in Japan to discuss the regulatory path for XDEMVY [4][10] Pipeline Developments - Tarsus is on track to initiate a Phase 2 study of TP-04 for Ocular Rosacea, a condition with no FDA-approved therapy, in H2 2025 [4][10] - The company is also developing TP-05, an investigational oral tablet for the potential prevention of Lyme disease, expected to begin trials in 2026 [5][10]

Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session at $50.90, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $67.13 indicates a 31.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $13.74. While the lowest estimate of $41 indicates a 19.5% decline from the current price level, the most optimist ...

Company Overview - Tarsus Pharmaceuticals, Inc. focuses on revolutionizing treatment for patients, particularly in eye care, by applying proven science and new technology [2] - The company is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including eye care and infectious disease prevention [2] Product Development - Tarsus has FDA approval for XDEMVY® (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis [2] - The company is developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease [2] Upcoming Events - Tarsus Pharmaceuticals will host a live webcast on May 1, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to report its first quarter 2025 financial results and provide a corporate update [1]

Core Insights - Tarsus Pharmaceuticals will present data on the global prevalence and patient burden of Demodex blepharitis, along with the efficacy of XDEMVY at the ASCRS 2025 Annual Meeting [1][2] Group 1: Demodex Blepharitis - Demodex blepharitis is a common eyelid disease caused by Demodex mites, affecting over two-thirds of blepharitis cases and potentially impacting 25 million Americans [7] - The Titan study indicates that 58% of patients visiting U.S. eye care clinics show signs of Demodex mite infestation, with 45 million annual visits to eye care clinics [7] Group 2: XDEMVY (Lotilaner Ophthalmic Solution) - XDEMVY is a novel prescription eye drop designed to treat Demodex blepharitis by targeting the underlying mite infestation [8] - Clinical trials involving over 800 patients demonstrated that XDEMVY met primary and secondary endpoints with statistical significance and no serious treatment-related adverse events [8][9] - The most common side effect reported was stinging and burning in 10% of patients, while other adverse reactions were less than 2% [9][11] Group 3: Upcoming Presentations - The ASCRS meeting will feature several presentations, including: - A longitudinal evaluation of disease burden and treatment efficacy in patients with Demodex blepharitis [3] - A study assessing specific symptoms of Demodex blepharitis [4] - Research on the treatment of Demodex blepharitis in patients with Meibomian gland dysfunction [5] - An observational study on the prevalence of Demodex blepharitis in Japan [6]

Group 1 - Tarsus Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 2,808,988 shares at a public offering price of $44.50 per share, with expected gross proceeds of approximately $125.0 million before deductions [1] - The offering is expected to close on March 14, 2025, subject to customary closing conditions [1] - Underwriters have a 30-day option to purchase an additional 421,348 shares at the public offering price [1] Group 2 - Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the offering [2] - A registration statement for the shares was filed with the U.S. Securities and Exchange Commission (SEC) on February 29, 2024, and became effective upon filing [3] - A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on their website [4] Group 3 - Tarsus Pharmaceuticals focuses on advancing its pipeline to address diseases with high unmet needs, particularly in eye care and infectious disease prevention [6] - The company’s FDA-approved product, XDEMVY, is for the treatment of Demodex blepharitis, and it is also developing TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention [6]

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and ...

IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET. A live webcast and additional information can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceutical ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - W ...

Fourth Quarter and Full-Year 2024 Financial Results Conference Call February 25, 2025 Matt, an XDEMVY® Patient Today's Speakers Bobby Azamian, MD, PhD CEO & Chairman Jeff Farrow Chief Financial & Strategy Officer Aziz Mottiwala Chief Commercial Officer Sesha Neervannan, PhD Chief Operating Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements include statements ...

Financial Performance - XDEMVY generated $66.4 million in net product sales for Q4 2024 and $180.1 million for the full year 2024[521]. - Total revenues for the year ended December 31, 2024, were $182.9 million, a significant increase from $17.4 million in 2023[564]. - The net loss for the year ended December 31, 2024, was $115.6 million, an improvement from a net loss of $135.9 million in 2023[564]. - Total net cash provided by financing activities was $154.7 million for 2024, primarily from $98.3 million in net proceeds from a public offering and $75.0 million from an initial draw against the 2024 Credit Facility[603]. - The company reported a significant increase in accounts receivable, netting $46.760 million in 2024 compared to $16.621 million in 2023, suggesting improved sales performance[630]. - The company’s accumulated deficit increased to $360.210 million in 2024 from $244.656 million in 2023, highlighting ongoing financial challenges[630]. - The net loss for 2024 was $115.554 million, compared to a net loss of $135.893 million in 2023, indicating an improvement in financial performance[632]. Product Sales and Market Performance - Over 58,500 bottles of XDEMVY were dispensed in Q4 2024, totaling 163,000 bottles for the full year 2024[521]. - Product sales, net increased by $165.3 million to $180.1 million for the year ended December 31, 2024, driven by over 163,000 bottles of XDEMVY dispensed compared to 17,400 bottles in the prior year[565]. - XDEMVY was commercially launched in August 2023 following FDA approval in July 2023, contributing to the significant increase in product sales[565]. - Major customers accounted for 61% of gross revenue in 2024, down from 99% in 2023, with Customer A contributing 47% in 2024[677]. - Customer A represented 55% of accounts receivable in 2024, compared to 13% in 2023, indicating increased reliance on this customer[677]. Research and Development - Positive topline results from the Ersa trial showed statistically significant improvements in Meibomian Gland Disease metrics[523]. - The Galatea trial for TP-04 demonstrated statistically significant improvements in inflammatory lesions and Investigator's Global Assessment score[525]. - The Carpo trial for TP-05 showed statistical significance in tick mortality compared to the vehicle (p<0.001)[526]. - The company expects to initiate a Phase 2 study for TP-04 in the second half of 2025 for Ocular Rosacea[525]. - Research and development expenses increased to $53.4 million in 2024 from $50.3 million in 2023, indicating ongoing investment in product development[564]. - Research and development expenses rose to $53.386 million in 2024 from $50.312 million in 2023, reflecting ongoing investment in innovation[632]. Operating Expenses - Operating expenses increased to $303.5 million in 2024 from $160.6 million in 2023, primarily due to higher selling, general and administrative expenses[564]. - Selling, general and administrative expenses rose to $237.3 million in 2024, up from $108.7 million in 2023, reflecting the costs associated with the commercialization of XDEMVY[561]. - Selling, general and administrative expenses increased by $128.6 million to $237.3 million, mainly due to $39.7 million in payroll costs and $52.0 million in commercial and marketing expenses[570]. - Advertising costs were $29.8 million and $9.4 million for the years ended December 31, 2024 and 2023, respectively[706]. Cash and Liquidity - As of December 31, 2024, the company had $291.4 million in cash, cash equivalents, and marketable securities[539]. - Cash and cash equivalents decreased to $94.819 million in 2024 from $224.947 million in 2023, reflecting a reduction in liquidity[630]. - The company reported a net cash used in operating activities of $83.0 million for the year ended December 31, 2024, compared to $117.5 million for 2023, indicating an improvement in operational cash flow[599][600]. - The company’s investing activities resulted in a net cash outflow of $199.2 million for 2024, primarily due to $262.6 million in purchased marketable securities[601]. Future Outlook and Obligations - The company expects to incur significant operating losses as it expands clinical development programs and continues to commercialize XDEMVY[590]. - The company has milestone obligations totaling up to $9.0 million for development milestones and up to $249.0 million for commercial and sales-based milestones[596]. - The company plans to fund operations using existing cash and investments, alongside cash generated from commercial operations[649]. - The company expects to recognize additional license fees and collaboration revenue under the China Out-License based on future milestone achievements[567]. Compliance and Risk Management - The company has served as the auditor since 2020, ensuring compliance with PCAOB standards and maintaining independence in financial reporting[627]. - The company relies on third-party manufacturers for the production of XDEMVY, which poses a risk of disruption if key suppliers are lost[678]. - The company has established guidelines for diversification of investments to mitigate credit risk, with no losses reported to date[674]. - The company has not experienced significant credit risk due to the financial position of its depository institutions[674].